Antibodies (abs) against the enzyme glutamic acid decarboxylase (GAD) are found in a variety of neurological disorders. Treatment options in these disorders are still limited and the role of the GAD-abs in disease development is incompletely understood. Our aim is to identify the immune cells that produce the GAD-abs and to understand the immunological mechanisms that trigger the autoimmune response in GAD-ab-associated neurological disorders. Further, we will study the pathogenicity of the GAD-abs. Hereby, we hope to contribute to the development of more specific and more effective treatment options in the future. 

Here you can get further information.